Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

References

• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401–6.
   PubMed Web of Science ®Google Scholar
• Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2010; 305:250–62.
   Google Scholar
• Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM. Commentary: aspirin and colorectal cancer an epidemiological success story. Int J Epidemiol. 2007;36:962–5.
   Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, . Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.
   PubMed Web of Science ®Google Scholar
• Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, . Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175:1197–205.
   PubMed Web of Science ®Google Scholar
• Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, . The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119:3011–23.
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, . NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
   PubMed Web of Science ®Google Scholar
• Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, . The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67:585–92.
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol. 2008(181):101–29.
   Google Scholar
• Nakada MT, Tam SH, Woulfe DS, Casper KA, Swerlick RA, Ghrayeb J. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun. 1998;5:491–503.
   PubMed Web of Science ®Google Scholar
• Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, . A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer. 2010;103:1149–53.
   Google Scholar
• Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185–98.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, . Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–20.
   PubMed Web of Science ®Google Scholar
• Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82:1022–4.
   Google Scholar
• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–33.
   PubMed Web of Science ®Google Scholar
• Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001;12:2035–49.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med. 2002;6:160–74.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, . Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.
   PubMed Web of Science ®Google Scholar
• Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382–7.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med. 1998;187:1885–92.
   PubMed Web of Science ®Google Scholar
• Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol Ther. 2007;6:840–5.
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–5.
   PubMed Web of Science ®Google Scholar
• Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7:E14–9.
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18: 1185–90.
   PubMed Web of Science ®Google Scholar
• Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, . Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer. 2010;46:198–206.
   PubMed Web of Science ®Google Scholar
• Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, . Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;103:837–44.
   Web of Science ®Google Scholar
• Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, Carraro F. Interleukin-1beta regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1alpha. Eur J Cancer. 2010;46:3400–8.
   PubMed Web of Science ®Google Scholar
• Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006;4:48.
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, . IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–50.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307–13.
   PubMed Web of Science ®Google Scholar
• Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, . The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25:387–408.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010;29:317–29.
   PubMed Web of Science ®Google Scholar
• Arguello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Effect of IL-1 on experimental bone/bone-marrow metastases. Int J Cancer. 1992;52:802–7.
   PubMed Web of Science ®Google Scholar
• Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, . Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol. 2003;171:6448–56.
   PubMedGoogle Scholar
• Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, . The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009;183:4705–14.
   Google Scholar
• Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, . Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008;14:156–65.
   PubMed Web of Science ®Google Scholar
• Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res. 1993;53:5051–4.
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 1994;54:2667–72.
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, . Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84:114–22.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, . Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–25.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, . Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–52.
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–83.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109–19.
   PubMed Web of Science ®Google Scholar
• Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21:1714–9.
   PubMed Web of Science ®Google Scholar
• van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, . Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest. 1996;98:1441–8.
   PubMed Web of Science ®Google Scholar
• Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K, . C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood. 2009;114:3890–8.
   PubMed Web of Science ®Google Scholar
• Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, . Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol. 1997;151:689–96.
   PubMed Web of Science ®Google Scholar
• Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223–31.
   PubMed Web of Science ®Google Scholar
• Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, . Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–6.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115–30.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, . Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131–44.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, . IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009 Feb 3;15(2): 103–13.
   Google Scholar
• Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, . A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323–34.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li PK, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem. 2010;285:27429–39.
   Google Scholar
• Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991;13:267–76.
   PubMed Web of Science ®Google Scholar
• Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, . Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol. 1991;86:1804–8.
   PubMedGoogle Scholar
• Malaguarnera M, Di Fazio I, Laurino A, Ferlito L, Romano M, Trovato BA. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther. 1997;35:385–8.
   Google Scholar
• Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336–43.
   PubMed Web of Science ®Google Scholar
• Gregg SD, Campbell JL, Fisher JW, Bartlett MG. Methods for the characterization of Jet Propellent-8: vapor and aerosol. Biomed Chromatogr. 2007;21:463–72.
   PubMed Web of Science ®Google Scholar
• Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, . PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31:455–61.
   Google Scholar
• Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci. 2011;102:769–75.
   Google Scholar
• Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, . Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750–7.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108:1397–402.
   PubMed Web of Science ®Google Scholar
• Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011;10:481–94.
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653–65.
   PubMed Web of Science ®Google Scholar
• Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, . Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther. 2007;6:2386–90.
   PubMed Web of Science ®Google Scholar
• Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4 Suppl 3:S233–42.
   Google Scholar
• Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010;10:369–73.
   PubMed Web of Science ®Google Scholar
• Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2010;317:664–73.
   Google Scholar
• Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026–9.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007;292:C987–95.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–31.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, . Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201–11.
   PubMed Web of Science ®Google Scholar
• Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, . Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009;69: 1460–9.
   PubMed Web of Science ®Google Scholar
• Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, . Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009;21:761–7.
   PubMed Web of Science ®Google Scholar
• Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, . CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2010;129: 225–32.
   Google Scholar
• De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009;77:1655–64.
   PubMed Web of Science ®Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43–52.
   PubMed Web of Science ®Google Scholar
• Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256: 137–65.
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, . Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest. 1998;102:465–72.
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Savino B, Borroni EM, Mantovani A, Locati M. Chemokine decoy receptors: structure-function and biological properties. Curr Top Microbiol Immunol. 2010;341:15–36.
   Google Scholar
• Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR + CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther. 2006;112:139–49.
   PubMed Web of Science ®Google Scholar
• Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med. 1997;186:1201–12.
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 1995;5:179–81.
   PubMed Web of Science ®Google Scholar
• Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, . Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med. 1994;179:1409–15.
   PubMed Web of Science ®Google Scholar
• Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, . CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8.
   PubMed Web of Science ®Google Scholar
• Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, . Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125–34.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006;97:1139–46.
   PubMed Web of Science ®Google Scholar
• Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, . Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.
   Google Scholar
• Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, . Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2009;58:1195–206.
   PubMed Web of Science ®Google Scholar
• Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869–75.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, . CD3 + cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009;10:877–84.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
   PubMed Web of Science ®Google Scholar
• Mantovani A. Cancer: an infernal triangle. Nature. 2007;448:547–8.
   PubMedGoogle Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196: 254–65.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40:1660–7.
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86: 1065–73.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, . Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–39.
   PubMed Web of Science ®Google Scholar
• Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, . Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother. 2009;58:1577–86.
   PubMed Web of Science ®Google Scholar
• Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol. 1997;27:2626–33.
   Google Scholar
• Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC. Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J Virol. 2010;84:7569–80.
   PubMed Web of Science ®Google Scholar
• Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95:272–81.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, . Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010;16:3420–30.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, . First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–99.
   PubMed Web of Science ®Google Scholar
• Hembruff SL, Jokar I, Yang L, Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia. 2010;12:425–33.
   Google Scholar
• Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, . Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417–24.
   PubMed Web of Science ®Google Scholar
• Rozel S, Galban CJ, Nicolay K, Lee KC, Sud S, Neeley C, . Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem. 2009;107:58–64.
   Google Scholar
• Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, . A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009;69:1685–92.
   Google Scholar
• Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, . Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 2009;69:7884–92.
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003;63:8360–5.
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, . Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005;65:2964–71.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, . Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235–44.
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9:2157–63.
   PubMed Web of Science ®Google Scholar
• Roodink I, Leenders WP. Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett. 2010;299:1–10.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, . G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106:6742–7.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65:3437–46.
   PubMed Web of Science ®Google Scholar
• Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 2011;20:361–72.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Bronte V. Control of immune response by amino acid metabolism. Immunol Rev. 2010;236:243–64.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, . Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11:312–9.
   PubMed Web of Science ®Google Scholar
• Kanchanawong P, Shtengel G, Pasapera AM, Ramko EB, Davidson MW, Hess HF, . Nanoscale architecture of integrin-based cell adhesions. Nature. 2011;468:580–4.
   Google Scholar
• Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets. 2010;14:77–94.
   PubMed Web of Science ®Google Scholar
• Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2010;19:777–88.
   PubMed Web of Science ®Google Scholar
• McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, . Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 2004;18:2998–3003.
   PubMed Web of Science ®Google Scholar
• Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 1999;112 (Pt 16):2677–91.
   PubMedGoogle Scholar
• Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002;21:6289–302.
   PubMedGoogle Scholar
• Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, . Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006;25:5969–84.
   PubMedGoogle Scholar
• Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, . Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 2006;177:4267–70.
   Google Scholar
• Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, . Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 2009;69:3308–16.
   PubMed Web of Science ®Google Scholar
• Chen YY, Wang ZX, Chang PA, Li JJ, Pan F, Yang L, . Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci. 2009; 100:1708–13.
   PubMed Web of Science ®Google Scholar
• Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer. 2009;8:125.
   PubMed Web of Science ®Google Scholar
• Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, . Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol. 2004;41: 104–11.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Fan J, Wu ZQ, Zhou J, Qiu SJ. [Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC]. Zhonghua Yi Xue Za Zhi. 2007;87:1256–9.
   PubMedGoogle Scholar
• Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, . High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 2005;18:1289–94.
   PubMed Web of Science ®Google Scholar
• Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, zur Hausen A. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int J Gynecol Cancer. 2009;19:1221–5.
   PubMed Web of Science ®Google Scholar
• Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, . Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res. 2009;33:764–8.
   PubMed Web of Science ®Google Scholar
• Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009;119:252–66.
   PubMed Web of Science ®Google Scholar
• Theocharis SE, Kouraklis GP, Kakisis JD, Kanelli HG, Apostolakou FE, Karatzas GM, . Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients. Eur J Surg Oncol. 2003;29:571–4.
   PubMed Web of Science ®Google Scholar
• Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K, . Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006;30: 219–26.
   PubMed Web of Science ®Google Scholar
• Yu HG, Nam JO, Miller NL, Tanjoni I, Walsh C, Shi L, . p190RhoGEF (Rgnef) Promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. Cancer Res. 2011;71:360–70.
   Google Scholar